Richard Wilson

Professor Richard Wilson serves as Professor of Gastrointestinal Oncology at the Institute of Clinical Sciences, University of Glasgow, and is an Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre. Previously, he was a Senior Lecturer at Queen's University Belfast and Consultant Oncologist at Belfast City Hospital.

• Graduated from Queen's University Belfast in 1984
• Completed clinical oncology training followed by post-CCT Fellowship at the National Cancer Institute in the USA
• Appointed Senior Lecturer at Queen's University Belfast in 2001
• Joined University of Glasgow in 2019 as Professor in Gastrointestinal Oncology

Professor Wilson's research spans gastrointestinal cancer (particularly colorectal, small bowel, and anal cancer), drug development, biomarkers, personalized medicine, and early/late phase clinical trials. His work integrates cancer biology, translational research, and clinical applications to advance cancer treatment. He has established significant research programs including the first early phase cancer clinical trials program on the island of Ireland and the International Rare Cancer Initiative Small Bowel Adenocarcinoma Working Group.

His publication record reveals consistent contributions to colorectal cancer research with focus areas including molecular subtyping, targeted therapies, immunotherapy approaches, and clinical trial design. Recent work emphasizes personalized medicine approaches and biomarker-driven treatment strategies.

• Chair of Colorectal Cancer Clinical Studies Group (2014-2017)
• Co-Chair of International Rare Cancer Initiative Small Bowel Adenocarcinoma Working Group
• Member of Medical Advisory Board for Bowel Cancer UK (since 2013)
• First Clinical Director of the N. Ireland Cancer Trials Network

Professor Wilson leads the Glasgow Clinical Academic Training component of the TRACC programme, which provides PhD positions for postgraduate trainees and intercalating medical and dental students. He has secured multiple substantial research grants including projects investigating BRAF V600E mutated colorectal cancer, BRAF-driven systemic neutrophilia, and the BALLAD global study for small bowel adenocarcinoma. His leadership extends to major clinical trial initiatives including the FOCUS4 trial program for metastatic colorectal cancer.

He directs research teams focused on gastrointestinal oncology, with particular expertise in colorectal cancer biology, clinical trial design, and translational research. His laboratory work spans from basic cancer biology to clinical implementation, maintaining strong connections between discovery science and clinical practice.